 |
|
Therapeutic peptide frees the protein p73 to kill tumor cells
March 09, 2007The protein p53 suppresses tumor development by potently inducing tumor cell death, making it an obvious target for anticancer therapeutics. However, this therapeutic approach is confounded by the fact that genetic mutations cause loss or inactivation of p53 in approximately 50% of human cancers. As the p53-related protein p73, which can also induce tumor cell death, is rarely mutated in human cancers, researchers from the Beatson Institute for Cancer Research, United Kingdom, hypothesized that it might represent a more viable target than p53 for the development of broadly applicable anticancer therapeutics.
In the study, which appears online on March 8 in advance of publication in the April print issue of the Journal of Clinical Investigation, Kevin Ryan and colleagues show that a peptide of 37 amino acids in length, which they generated from human p53 (termed 37AA), killed both p53-sufficient and p53-deficient human tumor cell lines. 37AA mediated tumor cell death by binding to the negative regulator of p53-family proteins iASPP and preventing it from repressing the death-inducing function of p73. Furthermore, systemic administration of 37AA to mice with established tumors of human origin (both p53-sufficient and p53-deficient tumors) induced tumor regression in a p73-dependent manner. These data suggest that targeting the p73-mediated pathway of tumor cell death might provide a new avenue of research for the development of anticancer therapeutics.
Journal of Clinical Investigation
Inhibitor of heat shock protein is a potential anticancer drug, Penn study finds
Like yoga for office drones, cells do have coping strategies for stress. Heat, lack of nutrients, oxygen radicals - all can wreak havoc on the delicate internal components of a cell, potentially damaging it beyond repair.
Discovery could lead to better control of hemorrhagic fever viruses
Researchers report discovering the receptor through which a group of life-threatening hemorrhagic fever viruses enter and attack the body's cells, and show that infection can be inhibited by blocking this receptor.
Molecular pathway linked to breast cancer recurrence
A study published in the September issue of Cancer Cell provides new evidence for a genetic pathway that is involved in the recurrence of breast cancer and identifies a potential target for development of new anticancer therapeutics.
EU funding helping to find ocean remedies for cancer
European Union funding is helping to find cancer treatments for certain deadly tumours using small marine animals. European researchers are using chemical agents extracted from a type of Caribbean sea squirt, named Ecteinascidia turbinata, to treat some tumours. The breakthrough findings will soon be published in the Marine Drugs journal. The project on "A novel marine pharmaceutical with unique mechanism of action for the treatment of cancer", has helped to establish trials in 24 EU centres across seven European countries. The project, involving Dutch, French and Spanish participants, aims to test the chemicals in treating sarcomas, a rare tumour that kills about 3,900 Europeans a
More Anticancer Therapeutics Current Events and Anticancer Therapeutics News Articles
 |
Anticancer Therapeutics by Sotiris Missailidis (Author) Written by the winner of the 2008 Mike Price Fellowship "This volume provides a comprehensive overview of the wealth of information now available in this important and fast-moving subject." Anticancer Research, November - December 2008 This book provides a clear introduction to the area, with an overview of the various drug design and development approaches for cancer therapeutics and their progress in today’s multidisciplinary approach to cancer treatment. Clearly structured throughout, the book not only provides information on currently used molecular treatment approaches, but also describes the various agents that are currently at various stages of development and clinical trials, thus making them the drugs of tomorrow. The book goes on to... |
 |
Macromolecular Anticancer Therapeutics (Cancer Drug Discovery and Development) by L. Harivardhan Reddy (Editor), Patrick Couvreur (Editor) In spite of the development of various anticancer drugs, the therapy of cancer has remained challenging for decades. The current therapy of cancer is overwhelmed because of the inability to deliver therapeutics to all regions of a tumor in effective therapeutic concentrations, intrinsic or acquired resistance to the treatment with currently available agents via genetic and epigenetic mechanisms, and toxicity. As a result, cancer therapy using conventional therapeutics and different types of treatment regimens using this therapeutics has not led to a convincing survival benefit of the patients. In this context, Macromolecular therapeutics offer several advantages over conventional low molecular therapeutics by various ways such as, enable the use of larger doses of these agents by... |
|
Recent Advances in Clinical Therapeutics: Antivirals and Antimicrobials, Anticancer Agents, and Cardiovascular Therapy (v. 3) by Jack Z. Yetiv (Editor), Joseph R. Bianchine (Editor) | |
|
Lorus Therapeutics patents to protect lead anticancer target.(ribonucleotide reductase): An article from: BIOTECH Patent News by Biotech Patent News (Publisher) This digital document is an article from BIOTECH Patent News, published by Biotech Patent News on March 1, 2003. The length of the article is 3774 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Lorus Therapeutics patents to protect lead anticancer target.(ribonucleotide reductase) Publication: BIOTECH Patent News (Newsletter) Date: March 1, 2003 Publisher: Biotech Patent News Volume: 17 Issue: 3 Distributed by Thomson Gale | |
|
Reduction of Anticancer Drug Toxicity: Pharmacologic, Biologic, Immunologic and Gene Therapeutic Approaches (Contributions to Oncology, Vol 48) by W. J. Zeller (Editor), G. Eisenbrand (Editor), K. Hellmann (Editor) | |
 |
Anticancer Agents: Frontiers in Cancer Chemotherapy (Acs Symposium Series) by Iwao Ojima (Editor), Gregory D. Vite (Editor), Karl-Heinz Altmann (Editor) Describes cutting edge approaches in the development of anticancer agents for chemotherapy. These new and interdisciplinary approaches are aimed at the development of tumor specific anticancer agents while increasing the potency against drug-resistant tumors. The volume includes an overview of new paradigms for cancer drug discovery and development by NCI, new generation cytotoxic agents, mechanism based enzyme inhibitors as anticancer agents, anti-angiogenesis agents, antitumor vaccines, and tumor activated prodrugs using immunoconjugates of monoclonal antibodies with cytotoxic agents. |
|
DHEA: The anti-aging, anti-cancer and anti-obesity hormone (Woodland health series) by Rita Elkins (Author) | |
 |
Camptothecins New Anticancer Agents by Milan Potmesil (Author), Herbert M. Pinedo (Author) This exciting new book presents the first comprehensive overview of clinical trials of camptothecins, a new class of anticancer agents. Camptothecins are synthetic and semisynthetic derivatives of a plant alkaloid that inhibit a cellular enzyme and trigger a cascade of events leading to programmed cell death. Special attention is given to the adverse effects of camptothecin treatment, as well as to prevention and control. The book boasts contributions by some of the most respected authorities in camptothecin research, who haveoConducted much of the pre-clinical work which helped to renew interest in camptothecinsoDiscovered and identified the natural product camptothecin and synthesized most of the anloguesoDiscovered the mechanism of camptothecin cytotoxicity |
 |
An Introduction to the Use of Anticancer Drugs by Imran Rafi (Author) This book introduces the commonly prescribed drugs in the treatment of the solid cncers. It highlights the principles of use of anticancer drugs, the side effects associated with them and the commonly used drug regimes for tumour specific diseases. Case studies are used to highlight typical drug treatment regimes for patients. The NICE guidelines are listed. * Basic principles of drug treatment - develops an understanding of why and when anticancer drugs are used. * Covers the purpose of clinical trials in oncology from Phase I to Phase IV trials in drug development. * Discusses the organisation of clinical networks in the UK. * Case studies in cancer treatment, allowing an understanding of when and why the typical regimes are used. * NICE guidelines. |
 |
The Search for New Anti-Cancer Drugs (Cancer Biology and Medicine) by M.J. Waring (Editor), B.A. Ponder (Editor) Most of the anti-cancer drugs in use today were discovered by happy accident rather than design, yet the rational design of better anti-cancer drugs remains a cherished goal, and one of the most important challenges facing medical science. This book represents a compilation of views and progress reports which illustrate the diversity of approaches to the problem. Recent research has confirmed the belief that critical genetic changes are at work in cancer cells. The genome, then (DNA in biochemical terms), surely represents a critical target for specific chemotherapy of cancer, and several chapters address the issue of attacking DNA, gene targetting, and the like. Others deal with principles of rational design, exploitation of novel modalities and targets, or the nuts and bolts... |
| © 2009 BrightSurf.com |